PT-141 (Bremelanotide) — 10mg

PT-141 (Bremelanotide) is a synthetic cyclopeptide that acts as a melanocortin receptor agonist with a unique mechanism of action for sexual function. It is FDA approved as Vyleesi® for hypoactive sexual desire in premenopausal women (2019). Each vial contains 10mg of lyophilized PT-141, ≥99% purity, HPLC tested. PT-141 differs fundamentally from PDE-5 inhibitors (Viagra, Cialis): it works via the central nervous system through activation of melanocortin-3 and -4 receptors in the hypothalamus — not via vasodilation. This makes it effective in forms of sexual dysfunction where vascular interventions are insufficient. PT-141 increases sexual desire and arousal via neurochemical pathways. As a derivative of Melanotan II it was originally researched for skin pigmentation, where the sexual side effect was discovered, leading to targeted therapeutic development. In research protocols: doses of 1–2mg subcutaneous 45–60 minutes before use. The effects last 6–12 hours. Reconstitution with bacteriostatic water required. For laboratory and research purposes only.

Post Cycle Therapy (PCT) is not required after PT-141 use. It has no effect on the HPTA axis.